P809: BASELINE CHARACTERISTICS IDENTIFYING PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICELEUCEL (IDE‐CEL; BB2121) WHO ARE AT RISK FOR SEVERE/REFRACTORY INFLAMMATORY ADVERSE EVENTS

Saved in:
Bibliographic Details
Published inHemaSphere Vol. 7; no. S3; pp. e1004207 - n/a
Main Authors Mashadi‐Hossein, Afshin, Rytlewski, Julie, Shamsuzzaman, MD, Basudhar, Debashree, Takhar, Mandeep, Kostic, Ana, Campbell, Timothy B., Manier, Salomon, Lin, Yi, Martin, Nathan
Format Journal Article
LanguageEnglish
Published Philadelphia, PA Lippincott Williams & Wilkins 08.08.2023
Wiley
Online AccessGet full text

Cover

More Information
ISSN:2572-9241
2572-9241
DOI:10.1097/01.HS9.0000970140.10042.07